Why I Am Buying the Schwab International Equity ETF (SCHF) and Never Looking Back

The Schwab International Equity ETF (SCHF) is highlighted as a low-cost, broadly diversified international index fund holding more than 1,400 non‑U.S. companies and is market‑cap weighted, with top holdings including ASML, Samsung, Roche, HSBC and Novartis. Key metrics: 0.03% expense ratio, recent dividend yield ~3.4%, and strong historical average annual returns of 16.59% (3y), 9.39% (5y), 10.40% (10y) and 6.87% (15y). The piece frames SCHF as a compelling option for U.S.-biased portfolios seeking international exposure and income, while noting it was not among Motley Fool Stock Advisor’s top 10 picks.

Analysis

Market structure: A low-fee, high-dividend international ETF (SCHF) benefits exporters, large-cap European and Asian tech/health names (ASML, Samsung, Roche, NVS) via incremental inflows if U.S. growth softens. Market-cap weighting concentrates exposure to a handful of mega-caps, so index flows amplify idiosyncratic moves in semiconductor equipment and big pharma stocks. Cross-asset: sustained flows into SCHF imply modest USD weakening (200–500 bps FX impact on local returns) and rotate yield-sensitive cash out of Treasuries into foreign equities, pressuring core bond prices if sustained.

Risk assessment: Tail risks include a China growth shock, new export controls on chip equipment (ASML), or a European recession that could erase the 3.4% yield cushion; any of these could cause 20–35% drawdowns in region-heavy holdings. Short-term (days–weeks) volatility will track macro headlines and FX; medium-term (3–12 months) performance depends on rate differentials and trade policy; long-term (>12 months) depends on earnings recovery and currency normalization. Hidden dependency: SCHF is unhedged to local currencies — currency moves often explain >50% of quarterly variance.

Trade implications: Direct plays: overweight SCHF relative to SPY to express non-U.S. cyclicality, and selective longs in ASML and NVS for secular tech and defensive pharma exposure. Use pair trades (long SCHF, short SPY) to isolate regional beta and buy USD-puts or EUR-calls to hedge FX risk. Options: use 3–6 month protective puts on concentrated single-stock longs (ASML) and collars if collecting yield is needed.

Contrarian angles: Consensus sees SCHF as cheap diversification; it understates single-stock concentration and FX sensitivity — investors may be complacent about ASML-policy risk. Reaction may be underdone if the USD weakens sharply: international equities could outperform by 400–800 bps in 6–12 months, but the reverse is true if geopolitical/regulatory shocks hit semiconductor supply chains. Historic parallel: 2014–2016 EAFE vs S&P swings show multi-quarter reversals often driven by currency moves, not just earnings.

Key Decisions for Investors

• Establish a 2–3% net-long position in SCHF (Schwab International Equity ETF) within the next week to diversify away from U.S. beta; rebalance quarterly and trim if 12-month trailing total return underperforms SPY by >300 bps or SCHF dividend yield falls below 2.6%.
• Implement a market‑neutral regional pair: go long SCHF (2% of portfolio) and short SPY (2%) for 6–12 months to express international relative strength; close if SCHF outperforms by >500 bps or underperforms by >300 bps.
• Buy ASML (ASML) as a 0.75–1.0% conviction add, DCA in three tranches over 6 weeks; protect with a 3‑month 15% OTM put if cost ≤2% of position value or hedge with a collar if holding >3 months.
• Hedge currency/tail risk: purchase a 3–6 month USD‑put exposure sized to offset ~50% of SCHF FX exposure (e.g., buy puts on UUP or buy EUR calls) if EUR/USD moves 3% against the portfolio; unwind when USD weakens >5% from entry or when SCHF outperforms SPY by >400 bps.